Insider Selling: XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells 500,742 Shares of Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

XOMA Stock Down 2.9 %

Shares of NASDAQ XOMA opened at $26.48 on Wednesday. The stock has a fifty day moving average price of $28.06 and a 200 day moving average price of $28.11. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA Co. has a 12-month low of $19.50 and a 12-month high of $35.00. The company has a market cap of $311.93 million, a P/E ratio of -7.61 and a beta of 0.92.

XOMA (NASDAQ:XOMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.05. The business had revenue of $7.20 million during the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. Research analysts anticipate that XOMA Co. will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ellsworth Advisors LLC purchased a new stake in XOMA during the 3rd quarter worth $516,000. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. State Street Corp boosted its holdings in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Barclays PLC grew its stake in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares during the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

XOMA has been the topic of a number of research analyst reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a report on Thursday, January 16th. HC Wainwright reiterated a “buy” rating and set a $123.00 target price on shares of XOMA in a report on Tuesday, January 7th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.